Patents by Inventor Kareem Graham

Kareem Graham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DGAT1 inhibition for treatment of demyelinating inflammatory disease
    Patent number: 10226470
    Abstract: Methods are provided for treating autoimmune disease in a subject by inhibiting the activity of DGAT1.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 12, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kareem Graham, Eugene C. Butcher
  • DGAT1 INHIBITION FOR TREATMENT OF DEMYELINATING INFLAMMATORY DISEASE
    Publication number: 20170095483
    Abstract: Methods are provided for treating autoimmune disease in a subject by inhibiting the activity of DGAT1.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 6, 2017
    Inventors: Kareem Graham, Eugene C. Butcher
  • Small molecule CMKLR1 antagonists in demyelinating disease
    Patent number: 9265738
    Abstract: Compounds and methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). In some embodiments such methods include treating demyelinating inflammatory disease in a subject by administering an agent that antagonizes the activity of chemokine-like receptor 1 (CMKLR1) and/or a CMKLR1 ligand (e.g., chemerin or other endogenous CMKLR1 ligands). Candidate compounds include, without limitation, analogs and variants of 2-(alpha-naphthoyl)ethyltrimethylammonium iodide.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: February 23, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kareem Graham, Jian Zhang, Eugene C. Butcher, Brian A. Zabel
  • Small Molecule CMKLR1 Antagonists in Demyelinating Disease
    Publication number: 20150025153
    Abstract: Compounds and methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). In some embodiments such methods include treating demyelinating inflammatory disease in a subject by administering an agent that antagonizes the activity of chemokine-like receptor 1 (CMKLR1) and/or a CMKLR1 ligand (e.g., chemerin or other endogenous CMKLR1 ligands). Candidate compounds include, without limitation, analogs and variants of 2-(alpha-naphthoyl)ethyltrimethylammonium iodide.
    Type: Application
    Filed: January 15, 2013
    Publication date: January 22, 2015
    Inventors: Kareem Graham, Jian Zhang, Eugene C. Butcher, Brian A. Zabel
  • Novel Target for Regulating Multiple Sclerosis
    Publication number: 20120064092
    Abstract: Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.
    Type: Application
    Filed: October 14, 2011
    Publication date: March 15, 2012
    Inventors: Kareem Graham, Brian A. Zabel, Eugene C. Butcher
  • Target for regulating multiple sclerosis
    Patent number: 8038992
    Abstract: Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: October 18, 2011
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Department of Veterans Affairs
    Inventors: Kareem Graham, Brian A. Zabel, Eugene C. Butcher
  • TARGET FOR REGULATING MULTIPLE SCLEROSIS
    Publication number: 20090280113
    Abstract: Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.
    Type: Application
    Filed: May 11, 2009
    Publication date: November 12, 2009
    Inventors: Kareem Graham, Brian A. Zabel, Eugene C. Butcher